A survey of cancer specialists know confusion about who is funding biphosphonates
a survey of cancer specialists for breast cancer charity now found confusion about who is funding biphosphonates -. cheap drugs normally used to treat osteoporosis
drugs alter the bone tissue, which makes it more difficult for cancer cells to survive there, and are already used for patients with advanced prostate cancer.
have been hailed as having the potential to prevent about one of every 10 deaths from breast cancer, and could save the NHS millions of pounds each year. breast
cancer now estimates that about 27,000 women each year are being lost bisphosphonates, with the main reason cited is the lack of clear guidance on who should fund them.
The survey, which involved the responses of 125 cancer specialists, found 59 percent had not brought in the bisphosphonate for patients with breast cancer.
A quarter (24 percent) were introduced and 17 percent had partially done.
These are inexpensive and widely available drugs and the overwhelming evidence of their ability to save lives should have changed the practice for now
When asked about possible barriers to drug administration, 45 percent said they were waiting for funding decisions, 11 percent were waiting for clinical decisions and the rest were waiting for a variety of other reasons.
Baroness Delyth Morgan, chief executive of breast cancer now, called for a national policy on who would finance drugs, such as the center through the NHS England or through groups starting local clinics (CCG ).
She said: “While bisphosphonates are not routinely available to all patients eligible breast cancer, women’s lives unnecessarily being put at risk
According to the survey, 59 percent of the specialists had not been on bisphosphonates for their patients
“it is cheap and widely available drugs and the overwhelming evidence of their ability to save lives should have changed the practice for now.
“But they are still sitting on the shelf, blocked by bureaucratic inertia.
” We are fortunate to have many of the leading oncologists in the world working in the NHS, and make sure that have all the tools they need to deliver the best breast cancer treatment possible. “
research published in the medical journal the Lancet last year found drugs could prevent 1,000 deaths from breast one year cancer.
the total cost of the drug is estimated to be 43p per day per patient
postmenopausal women on bisphosphonates saw a reduction of 28 percent in the likelihood that your cancer will come back.
the drugs reduced the risk of dying from the disease during the first 10 years after diagnosis by 18 percent.
analysis of breast cancer now shows the cost of giving women drugs would be almost £ 17 million a year, but possible savings through women who need fewer bone scans is expected and the fact that 1,200 fewer women each year develop secondary breast cancer.
bisphosphonates can be taken for about three years, either as a daily tablet (ibandronate) cost 34p per day, or intravenously every six months (zoledronate) on 4p per day.
has the potential to prevent about one of every 10 deaths from breast cancer
total cost (including time care and monitoring of side effects) is estimated to 43p per day per patient.
Rob Coleman, professor of medical oncology at the University of Sheffield, said, “must be an absolute priority for all physicians and curator involved in providing services of breast cancer to ensure that this simple treatment and insurance is made available, as a matter of urgency “
professor Ian Smith, president of clinical breast Reference Group cancer, said.” it is deeply troubling that such a cheap treatment known to improve survival women with breast cancer is not being made available to all who could benefit.
“in order to provide the best care for breast quality patient UK cancer, the introduction of these drugs to all eligible women must now be our priority. “
the call is presented as a separate study for Breast Cancer Care found two-thirds (66 percent) of hospital trusts NHS England not know how many of their patients had secondary breast cancer incurable.
NHS England said that decisions on the funding of medicines were built locally
despite being mandatory since 2013, one-fifth (19 percent) of hospital foundations are not collecting data on the number of people diagnosed with incurable breast cancer and nearly half (47 percent) they are not registering the full number.
a spokesman for NHS England, said: “. The report of the independent panel of cancer includes a specific recommendation on the use of bisphosphonates
” We continue to work to realize the ambitions the report and will shortly publish an update on progress. “
NHS England said decisions on drug financing were built locally.
But he said its use would be considered by the National Institute of Health and take care of excellence (Nice) in the next guide.